MXL vs REGN
MaxLinear Inc (MXL) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
MaxLinear Inc (MXL) is a semiconductors company listed on NASDAQ.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported MXL revenue for 2024-12-31 was $360.5M. Net income was -$245.2M. Revenue was down 48.0% from 2023-12-31 to 2024-12-31. MXL currently screens at market cap $7.42B.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
MXL currently screens at market cap $7.42B. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the MXL and REGN stock pages for the full models.
Not investment advice.